Literature DB >> 31179483

Cytomegalovirus Viremia and Death After Hematopoietic Cell Transplantation: More Complex Than "To Have and Have Not"?

Miguel-Angel Perales1,2, Genovefa A Papanicolaou3,2.   

Abstract

Entities:  

Year:  2020        PMID： 31179483      PMCID： PMC7346759          DOI： 10.1093/cid/ciz492

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

1.  Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.

Authors:  J D Meyers; E C Reed; D H Shepp; M Thornquist; P S Dandliker; C A Vicary; N Flournoy; L E Kirk; J H Kersey; E D Thomas
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

2.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Authors:  Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah
Journal:  N Engl J Med       Date:  2017-12-06       Impact factor: 91.245

3.  Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Michelle K Yong; Paul U Cameron; Monica Slavin; C Orla Morrissey; Krystal Bergin; Andrew Spencer; David Ritchie; Allen C Cheng; Assia Samri; Guislaine Carcelain; Brigitte Autran; Sharon R Lewin
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

4.  Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.

Authors:  J M Goodrich; R A Bowden; L Fisher; C Keller; G Schoch; J D Meyers
Journal:  Ann Intern Med       Date:  1993-02-01       Impact factor: 25.391

5.  Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.

Authors:  Corinne Cayatte; Kirsten Schneider-Ohrum; Zhaoti Wang; Alivelu Irrinki; Nga Nguyen; Janine Lu; Christine Nelson; Esteban Servat; Lorraine Gemmell; Andrzej Citkowicz; Yi Liu; Gregory Hayes; Jennifer Woo; Gary Van Nest; Hong Jin; Gregory Duke; A Louise McCormick
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

6.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.

Authors:  C R Li; P D Greenberg; M J Gilbert; J M Goodrich; S R Riddell
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

7.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Authors:  Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta
Journal:  Blood       Date:  2016-02-16       Impact factor: 22.113

Review 8.  The human cytomegalovirus terminase complex as an antiviral target: a close-up view.

Authors:  G Ligat; R Cazal; S Hantz; S Alain
Journal:  FEMS Microbiol Rev       Date:  2018-03-01       Impact factor: 16.408

9.  Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.

Authors:  Margaret L Green; Wendy Leisenring; Hu Xie; T Christopher Mast; Yadong Cui; Brenda M Sandmaier; Mohamed L Sorror; Sonia Goyal; Sezen Özkök; Jessica Yi; Farah Sahoo; Louise E Kimball; Keith R Jerome; Morgan A Marks; Michael Boeckh
Journal:  Lancet Haematol       Date:  2016-02-20       Impact factor: 18.959
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.